Form 4: Kiniksa Pharmaceuticals CFO Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Mark Ragosa, CFO of Kiniksa Pharmaceuticals International, plc, sold 36,372 Class A Ordinary Shares at $11.97 and 36,372 Class A Ordinary Shares at $22.25 on March 12, 2025, according to a Form 4 filing.
Summary
- On March 12, 2025, Mark Ragosa, the Chief Financial Officer of Kiniksa Pharmaceuticals International, plc, executed transactions involving Class A Ordinary Shares.
- Ragosa sold 36,372 shares at a price of $11.97 and another 36,372 shares at a weighted average price of $22.25.
- These transactions were conducted under a pre-arranged 10b5-1 trading plan established on September 3, 2024.
- Following these transactions, Ragosa directly owns 22,958 Class A Ordinary Shares.
- Ragosa also disposed of 36,372 share options at a price of $11.97.
- After the transaction, Ragosa directly owns 28,288 share options.
- The share options vest in installments, starting with 25% on the first anniversary of September 1, 2022, and the remainder in 36 equal monthly installments thereafter.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing simply reports transactions under a pre-existing 10b5-1 plan. There is no indication of positive or negative sentiment towards the company's prospects.
Industry Context
This filing is a routine disclosure of insider trading activity. It is common for executives to utilize 10b5-1 plans to sell shares over time to avoid accusations of trading on inside information. The market will likely interpret this as a neutral event unless the size of the transaction is unusually large or there are other concerning factors.
Key Dates
| Date | Description |
|---|---|
| 2022-09-01 | Vesting commencement date for share options. |
| 2024-09-03 | Date of execution of the 10b5-1 plan. |
| 2025-03-12 | Date of the reported transactions (share sale and option disposal). |
| 2025-03-14 | Date of the Form 4 filing. |
| 2032-08-31 | Expiration date of the share options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.